VYVGART is the first treatment that uses a fragment of an IgG antibody to treat adults with anti-AChR antibody positive gMG. VYVGART is a fragment of an IgG antibody (IgG = immunoglobulin G)
VYVGART is a novel treatment for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG) (AChR = acetylcholine receptor)
VYVGART is specifically designed to attach to and block the neonatal Fc receptor (FcRn), resulting in the reduction of IgG antibodies, including the harmful AChR antibodies that cause gMG symptoms
Receptors called “FcRn” extend the life of IgG antibodies.
In gMG, this allows harmful AChR antibodies to continue causing gMG symptoms. But IgG antibodies, including harmful AChR antibodies, that cannot attach to an FcRn are removed by the body.
When harmful AChR antibodies that cause gMG symptoms are removed, they can no longer disrupt nerve-muscle communication.
It’s like trying to get a table at a busy restaurant, where FcRns are the tables. IgG antibodies that get a table can stay for dinner, but if there are no tables available, IgG antibodies have to leave. The same goes for VYVGART, but since VYVGART can take some tables, there are fewer tables available for IgG antibodies, including harmful AChR antibodies. Those who don’t get a table are then removed.
Prednisone is used to treat many different inflammatory conditions such as arthritis, lupus, psoriasis, ulcerative colitis, allergic disorders, gland (endocrine) disorders, and conditions that affect the skin, eyes, lungs, stomach, nervous system, or blood cells.
Intravenous immune globulin (“IVIG”) is a product made up of antibodies that can be given intravenously (through a vein). IVIG is given into a vein (“intravenously”), in an infusion that takes one hour or more. The amount of IVIG you need for each dose depends on your weight as well as the reason you are getting the IVIG:
Plasmapheresis/Apheresis is a process in which the fluid part of the blood, called plasma, is removed from blood cells by a device known as a cell separator. The separator works either by passing the blood at high speed to separate the cells from the fluid or by passing the blood through a membrane with pores so small that only the fluid part of the blood can pass through.
Eculizumab is the first treatment to be approved to treat adults with anti-AChR Ab+ gMG in more than 60 years. Soliris works to help manage anti-acetylcholine receptor antibody-positive generalized Myasthenia Gravis (anti-AChR Ab+ gMG) by focusing on a specific part of your immune system.
Rituximab is a genetically engineered antibody that depletes CD20+ B-cells and is Food and Drug Administration- approved for treatment of non-Hodgkin lymphoma, CD20+ CLL, and rheumatoid arthritis. It carries a favorable side effects profile.